Poor response to sintilimab plus chemotherapy in a pulmonary epithelioid hemangioendothelioma patient: a case report.
Immunotherapy
; 15(2): 77-83, 2023 02.
Article
de En
| MEDLINE
| ID: mdl-36695105
Pulmonary epithelioid hemangioendothelioma (PEH) is a rare vascular tumor with no established treatment protocol. Although PD-1 inhibitors have dramatically improved the prognosis of some tumors, the efficacy is unknown in PEH patients. The authors report an advanced PEH patient treated with sintilimab plus platinum-based chemotherapy, who died after two cycles of treatment. The authors inferred that PEH patients with a germline PALB2 mutation and WWTR1-CAMTA1 fusion may not benefit from PD-1 inhibitors plus chemotherapy.
Mots clés
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Hémangioendothéliome épithélioïde
/
Tumeurs du poumon
Type d'étude:
Diagnostic_studies
/
Guideline
/
Prognostic_studies
Limites:
Female
/
Humans
Langue:
En
Journal:
Immunotherapy
Sujet du journal:
ALERGIA E IMUNOLOGIA
/
TERAPEUTICA
Année:
2023
Type de document:
Article
Pays d'affiliation:
Chine